Drug Type Small molecule drug |
Synonyms TAK 994, TAK994 |
Target |
Action agonists |
Mechanism OX2R agonists(Orexin receptor type 2 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (China), PRIME (European Union), Breakthrough Therapy (United States) |
Molecular FormulaC22H25F3N2O4S |
InChIKeyVOSAWOSMGPKQEQ-OALUTQOASA-N |
CAS Registry2274802-95-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cataplexy | Phase 2 | United States | 28 Feb 2020 | |
Cataplexy | Phase 2 | Canada | 28 Feb 2020 | |
Cataplexy | Phase 2 | Czechia | 28 Feb 2020 | |
Cataplexy | Phase 2 | Finland | 28 Feb 2020 | |
Cataplexy | Phase 2 | France | 28 Feb 2020 | |
Cataplexy | Phase 2 | Hungary | 28 Feb 2020 | |
Cataplexy | Phase 2 | Italy | 28 Feb 2020 | |
Cataplexy | Phase 2 | Netherlands | 28 Feb 2020 | |
Cataplexy | Phase 2 | Spain | 28 Feb 2020 | |
Narcolepsy | Phase 2 | Netherlands | 28 Feb 2020 |
Phase 2 | 97 | Placebo (Part A: Placebo) | bymlmlmbsj = ojmkqxvkeu jeriknggkm (hcsivxxwir, rvahwtzpnk - kpvfkehlry) View more | - | 29 Oct 2024 | ||
(Part A: TAK-994 120 mg) | bymlmlmbsj = tlikikqycj jeriknggkm (hcsivxxwir, vorxqnvgih - nqkqvosarx) View more | ||||||
Not Applicable | - | TAK-994 high-dose (HD) | gaiwoaizrw(irmtugezjg) = Urinary-related events were the most frequently reported TEAEs with TAK-994 imeiojrian (jzjuvtlfbw ) | - | 23 Oct 2023 | ||
TAK-994 low-dose (LD) | |||||||
Phase 2 | 73 | nzofoddulf(xauovkwvkr) = yphnikuavt ejkmobmljt (flhjxxgtvs ) View more | Negative | 27 Jul 2023 | |||
nzofoddulf(xauovkwvkr) = zryuagnwul ejkmobmljt (flhjxxgtvs ) View more |